Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 513, Issue 1-2, Pages 183-190Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2016.08.059
Keywords
Pertussis; PLGA nano/micro particles; Phagocytosis; Adjuvant
Categories
Funding
- National Natural Science Foundation of China [81301309, 51373199]
- British Council Innovation Initiative Award
- Innovative Research Team on Immunobiomaterials in Peking Union Medical College
- The British Council [GII112] Funding Source: researchfish
Ask authors/readers for more resources
Poly(lactic-co-glycolic acid) (PLGA) based nano/micro particles were investigated as a potential vaccine platform for pertussis antigen. Presentation of pertussis toxoid as nano/micro particles (NP/MP) gave similar antigen-specific IgG responses in mice compared to soluble antigen. Notably, in cell line based assays, it was found that PLGA based nano/micro particles enhanced the phagocytosis of fluorescent antigen-nano/micro particles by J774.2 murine monocyte/macrophage cells compared to soluble antigen. More importantly, when mice were immunised with the antigen-nano/micro particles they significantly increased antigen-specific Th1 cytokines INF-gamma and IL-17 secretion in splenocytes after in vitro restimulation with heat killed Bordetalla pertussis, indicating the induction of a Th1/Th17 response. Also, presentation of pertussis antigen in a NP/MP formulation is able to provide protection against respiratory infection in a murine model. Thus, the NP/MP formulation may provide an alternative to conventional acellular vaccines to achieve a more balanced Th1/Th2 immune response. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available